Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Puma Biotechnology Inc. (PBYI)

10.36   0.27 (2.68%) 09-20 20:36
Open: 10.2 Pre. Close: 10.09
High: 10.38 Low: 9.82
Volume: 1,298,769 Market Cap: 420M
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 272 full-time employees. The firm focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. The company focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.392 - 10.432 10.432 - 10.472
Low: 9.718 - 9.765 9.765 - 9.811
Close: 10.282 - 10.356 10.356 - 10.43

Technical analysis

as of: 2020-09-18 4:34:20 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 13.06     One year: 15.25
Support: Support1: 9.86    Support2: 9.04
Resistance: Resistance1: 11.18    Resistance2: 13.06
Pivot: 9.91
Moving Average: MA(5): 10.15     MA(20): 10.03
MA(100): 10.54     MA(250): 9.65
MACD: MACD(12,26): -0.06     Signal(9): -0.12
Stochastic oscillator: %K(14,3): 75.96     %D(3): 67.95
RSI: RSI(14): 54.72
52-week: High: 15.00  Low: 5.50  Change(%): -13.0
Average Vol(K): 3-Month: 82444  10-Days: 73092

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
PBYI has closed below upper band by 6.4%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to PBYI's normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sun, 20 Sep 2020
Puma Biotechnology Inc (NASDAQ:PBYI) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Sun, 20 Sep 2020
The Lead Independent Director of Puma Biotechnology, Inc. (NASDAQ:PBYI), Jay Moyes, Just Sold 62% Of Their Holding - Simply Wall St

Sat, 19 Sep 2020
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Sell at BidaskClub - MarketBeat

Tue, 15 Sep 2020
Puma Biotechnology Inc. [PBYI] Is Currently 8.00 below its 200 Period Moving Avg: What Dose This Mean? - The DBT News

Tue, 15 Sep 2020
Is a Correction Looming Ahead for Puma Biotechnology, Inc. (PBYI) - The News Heater

Tue, 15 Sep 2020
A Little Luck Can Go a Long Way with Puma Biotechnology Inc. (PBYI) as it 5-day change was 6.54% - News Daemon

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 40
Shares Float (M) 30
% Held by Insiders 11.59
% Held by Institutions 88.81
Shares Short (K) 7,450
Shares Short P. Month (K) 7,070

Stock Financials

EPS -1.060
EPS Est This Year -8.690
EPS Est Next Year -4.690
Book Value (p.s.) 0.590
Profit Margin -17.26
Operating Margin -12.07
Return on Assets (ttm) -7.2
Return on Equity (ttm) -184.3
Qtrly Rev. Growth 30.9
Gross Profit (p.s.) 5.933
Sales Per Share 6.075
EBITDA (p.s.) -0.532
Qtrly Earnings Growth
Operating Cash Flow (M) -1
Levered Free Cash Flow (M) 5

Stock Valuations

PE Ratio -9.77
PEG Ratio
Price to Book value 17.56
Price to Sales 1.71
Price to Cash Flow -391.51

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.